

九州がんセンター英文論文一覧 (2023)

4月～9月

#複合科学

外科切除非小細胞肺癌に対する人工知能予後予測モデルの開発についての論文

Kinoshita F, Takenaka T, Yamashita T, Matsumoto K, Oku Y, Ono Y, Wakasu S, Haratake N, Tagawa T, Nakashima N, Mori M

Development of artificial intelligence prognostic model for surgically resected non-small cell lung cancer

Sci Rep. 2023 SEP 21;13(1)

Journal Impact Factor 2021: 4.997

PMID: 37735585 (<https://pubmed.ncbi.nlm.nih.gov/37735585/>) DOI: 10.1038/s41598-023-42964-8

(<https://doi.org/10.1038/s41598-023-42964-8>) WoS: WOS:001075732600060

(<https://www.webofscience.com/wos/woscc/full-record/WOS:001075732600060>)

#外科学

膵純粋管状腺癌からの純粋扁平上皮癌成分からなる肝転移：症例報告についての論文

Mano Y, Sugimachi K, Shimagaki T, Tomino T, Onishi E, Lee L, Hisano T, Koga Y, Taguchi K, Morita M, Toh Y

Liver metastasis composed of pure squamous cell carcinoma component from pancreatic pure ductal adenocarcinoma: a case report

SURG CASE REP. 2023 SEP 29;9(1)

Journal Impact Factor 2021: N/A

PMID: 37773552 (<https://pubmed.ncbi.nlm.nih.gov/37773552/>) DOI: 10.1186/s40792-023-01755-z

(<https://doi.org/10.1186/s40792-023-01755-z>) WoS: WOS:001082524300001

(<https://www.webofscience.com/wos/woscc/full-record/WOS:001082524300001>)

#医学 #一般医療 #内科学 #第III相試験 #ランダム化比較試験

ホルモン受容体陽性進行乳癌におけるカピバセルチブについての論文

Turner NC, Oliveira M, Howell SJ, Dalenc F, Cortes J, Moreno HLG, Hu XC, Jhaveri K, Krivorotko P, Loibl S, Murillo SM, Okera M, Park YH, Sohn J, Toi M, Tokunaga E, Yousef S, Zhukova L, de Bruin EC, Grinsted L, Schiavon G, Foxley A, Rugo HS, CAPitello-291 Study Grp

Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer

N Engl J Med. 2023 JUN;388(22):2058-2070.

Journal Impact Factor 2021: 176.082

PMID: 37256976 (<https://pubmed.ncbi.nlm.nih.gov/37256976/>) DOI: 10.1056/NEJMoa2214131

(<https://doi.org/10.1056/NEJMoa2214131>) WoS: WOS:001078029600009

(<https://www.webofscience.com/wos/woscc/full-record/WOS:001078029600009>)

#泌尿器学 #腎臓学

骨修飾薬はラジウム223治療における症候性骨格イベントに対して保護的であることについての論文

Blas L, Shiota M, Matsumoto T, Hori Y, Nakamura M, Seki N, Kuroiwa K, Yokomizo A, Morokuma F, Kiyoshima K, Eto M

Bone-modifying agents are protective for symptomatic skeletal events in Radium-223 treatment

Int J Urol. 2023 JUL 27;

Journal Impact Factor 2021: 2.896

PMID: 37501328 (<https://pubmed.ncbi.nlm.nih.gov/37501328/>) DOI: 10.1111/iju.15259

(<https://doi.org/10.1111/iju.15259>) WoS: WOS:001038433600001

(<https://www.webofscience.com/wos/woscc/full-record/WOS:001038433600001>)

#消化器病学 #肝臓学

肝臓の慢性拡張性血腫：症例報告と文献レビューについての論文

Shimagaki T, Sugimachi K, Mano Y, Tomino T, Onishi E, Taguchi K, Morita M, Toh Y
Chronic expanding hematoma of the liver: a case report and review of the literature
Clin J Gastroenterol. 2023 SEP 26;

Journal Impact Factor 2021: N/A

PMID: 37751079 (<https://pubmed.ncbi.nlm.nih.gov/37751079>) DOI: 10.1007/s12328-023-01864-0
(<https://doi.org/10.1007/s12328-023-01864-0>) WoS: WOS:001070802200001
(<https://www.webofscience.com/wos/woscc/full-record/WOS:001070802200001>)

#腫瘍学

日本における浸潤性子宮頸癌に対するヒトパピローマウイルスワクチンの影響：がん統計およびMINT研究による予備的結果についての論文

Onuki M, Takahashi F, Iwata T, Nakazawa H, Yahata H, Kanao H, Horie K, Konnai K, **Nio A**, Takehara K, Kamiura S, Tsuda N, Takei Y, Shigeta S, Matsumura N, Yoshida H, Motohara T, Yamazaki H, Nakamura K, Hamanishi J, Tasaka N, Ishikawa M, Hirashima Y, Kudaka W, Mori-Uchino M, Kukimoto I, Fujii T, Watanabe Y, Noda K, Yoshikawa H, Yaegashi N, Matsumoto K, MINT Study Grp
Human papillomavirus vaccine impact on invasive cervical cancer in Japan: Preliminary results from cancer statistics and the MINT study
Cancer Sci. 2023 SEP 8;

Journal Impact Factor 2021: 6.518

PMID: 37688310 (<https://pubmed.ncbi.nlm.nih.gov/37688310>) DOI: 10.1111/cas.15943
(<https://doi.org/10.1111/cas.15943>) WoS: WOS:001066139900001
(<https://www.webofscience.com/wos/woscc/full-record/WOS:001066139900001>)

#腫瘍学

局所進行非小細胞肺癌に対するデュルバルマブと放射線治療の併用 DOLPHINフェーズ2非無作為化比較試験についての論文

Tachihara M, Tsujino K, Ishihara T, Hayashi H, Sato Y, Kurata T, Sugawara S, Shiraiishi Y, Teraoka S, Azuma K, Daga H, **Yamaguchi M**, Kodaira T, Satouchi M, Shimokawa M, Yamamoto N, Nakagawa K, WJOG
Durvalumab Plus Concurrent Radiotherapy for Treatment of Locally Advanced Non-Small Cell Lung Cancer The DOLPHIN Phase 2 Nonrandomized Controlled Trial
JAMA Oncol. 2023 SEP 7;

Journal Impact Factor 2021: 33.012

PMID: 37676681 (<https://pubmed.ncbi.nlm.nih.gov/37676681>) DOI: 10.1001/jamaoncol.2023.3309
(<https://doi.org/10.1001/jamaoncol.2023.3309>) WoS: WOS:001065186900005
(<https://www.webofscience.com/wos/woscc/full-record/WOS:001065186900005>)

#血液学 #第II相試験

再発または難治性の末梢性T細胞リンパ腫患者を対象としたダリナパルシン：アジア第2相試験の結果についての論文

Kim WS, Fukuhara N, Yoon DH, Yamamoto K, Uchida T, Negoro E, Izutsu K, Terui Y, Nakajima H, Ando K, **Suehiro Y**, Kang HJ, Ko PS, Nagahama F, Sonehara Y, Nagai H, Tien HF, Kwong YL, Tobinai K
Darinaparsin in patients with relapsed or refractory peripheral T-cell lymphoma: results of an Asian phase 2 study
Blood Adv. 2023 SEP 12;7(17):4903-4912.

Journal Impact Factor 2021: 7.642

PMID: 36661315 (<https://pubmed.ncbi.nlm.nih.gov/36661315>) DOI: 10.1182/bloodadvances.2022008615
(<https://doi.org/10.1182/bloodadvances.2022008615>) WoS: WOS:001069393000001
(<https://www.webofscience.com/wos/woscc/full-record/WOS:001069393000001>)

#腫瘍学 #観察研究 #多施設共同研究

RAS野生型転移性大腸癌における生物学的製剤併用一次化学療法の有効性における血漿血管新生因子の役割：GI-SCREEN CRC-Ukit試験の結果についての論文

Yuki S, Yamazaki K, Sunakawa Y, Taniguchi H, Bando H, Shiozawa M, Nishina T, Yasui H, Kagawa Y, Takahashi N, Denda T, **Esaki T**, Kawakami H, Satake H, Takashima A, Matsuhashi N, Kato T, Asano C, Abe Y, Nomura S,

Yoshino T

Role of plasma angiogenesis factors in the efficacy of first-line chemotherapy combined with biologics in RAS wild-type metastatic colorectal cancer: Results from the GI-SCREEN CRC-Ukit study
Cancer Med. 2023 AUG 28;

Journal Impact Factor 2021: 4.711

PMID: 37641470 (<https://pubmed.ncbi.nlm.nih.gov/37641470>) DOI: 10.1002/cam4.6486

(<https://doi.org/10.1002/cam4.6486>) WoS: WOS:001063719500001

(<https://www.webofscience.com/wos/woscc/full-record/WOS:001063719500001>)

#腫瘍学

MonarchEにおける閉経状態別の有効性と安全性の結果：HR+、HER2-、リンパ節転移陽性、高リスクの早期乳癌患者に対するアジュバントアベマシクリブと内分泌療法の併用療法についての論文

Paluch-Shimon S, Neven P, Huober J, Cicin I, Goetz MP, Shimizu C, Huang CS, Lueck HJ, Beith J, Tokunaga E, Contreras JR, de Sant'Ana RO, Wei R, Shahir A, Nabinger SC, Forrester T, Johnston SRD, Harbeck N, monarchE Investigators

Efficacy and safety results by menopausal status in monarchE: adjuvant abemaciclib combined with endocrine therapy in patients with HR+, HER2-, node-positive, high-risk early breast cancer
Ther Adv Med Oncol. 2023;15

Journal Impact Factor 2021: 5.485

PMID: 36756142 (<https://pubmed.ncbi.nlm.nih.gov/36756142>) DOI: 10.1177/17588359231151840

(<https://doi.org/10.1177/17588359231151840>) WoS: WOS:001061156800001

(<https://www.webofscience.com/wos/woscc/full-record/WOS:001061156800001>)

#腫瘍学 #多施設共同研究

HER2低値乳癌の有病率を推定し、臨床病理学的特徴、受けた治療、転帰を記述するレトロスペクティブ研究についての論文

Viale G, Basik M, Niikura N, Tokunaga E, Brucker S, Penault-Llorca F, Hayashi N, Sohn J, Sousa RTD, Brufsky AM, O'Brien CS, Schmitt F, Higgins G, Varghese D, James GD, Moh A, Livingston A, de Giorgio-Miller V

Retrospective study to estimate the prevalence and describe the clinicopathological characteristics, treatments received, and outcomes of HER2-low breast cancer

ESMO Open. 2023 AUG;8(4)

Journal Impact Factor 2021: 6.883

PMID: 37562195 (<https://pubmed.ncbi.nlm.nih.gov/37562195>) DOI: 10.1016/j.esmoop.2023.101615

(<https://doi.org/10.1016/j.esmoop.2023.101615>) WoS: WOS:001059373600001

(<https://www.webofscience.com/wos/woscc/full-record/WOS:001059373600001>)

#腫瘍学 #多施設共同研究

転移性大腸癌の脆弱な患者における実際の治療順序決定：多施設共同レトロスペクティブ研究についての論文

Mitani S, Kito Y, Hino K, Kawakami K, Izawa N, Hanamura F, Yamamoto Y, Shoji H, Komori A, Boku S, Tsuchihashi K, Kato K, Nonagase Y, Matsumoto T, Furuta M, Kawakami H

Real-World Treatment Sequencing in Vulnerable Patients with Metastatic Colorectal Cancer: A Multicenter Retrospective Study

Target Oncol. 2023 SEP;18(5):707-715.

Journal Impact Factor 2021: 4.897

PMID: 37668815 (<https://pubmed.ncbi.nlm.nih.gov/37668815>) DOI: 10.1007/s11523-023-00996-0

(<https://doi.org/10.1007/s11523-023-00996-0>) WoS: WOS:001058948300001

(<https://www.webofscience.com/wos/woscc/full-record/WOS:001058948300001>)

#腫瘍学

前治療歴のある肺癌患者における終末期の話し合いの要素と患者の転帰報告および実際の終末期ケアとの関連性についての論文

Hasegawa T, Okuyama T, Uemura T, Matsuda Y, Otani H, Shimizu J, Horio Y, Watanabe N, Yamaguchi T, Fukuda S, Oguri T, Maeno K, Taniguchi Y, Nosaki K, Fukumitsu K, Akechi T

Elements of End-of-Life Discussions Associated With Patients' Reported Outcomes and Actual End-of-Life Care in Patients With Pretreated Lung Cancer

Oncologist. 2023 SEP 5;

Journal Impact Factor 2021: 5.837

PMID: 37669003 (<https://pubmed.ncbi.nlm.nih.gov/37669003>) DOI: 10.1093/oncolo/oyad245

(<https://doi.org/10.1093/oncolo/oyad245>) WoS: WOS:001058738400001

(<https://www.webofscience.com/wos/woscc/full-record/WOS:001058738400001>)

#生化学 #分子生物学 #レビュー論文

癌の一般的特徴としての亜鉛欠乏：文献レビューについての論文

Sugimoto R, Lee L, Tanaka Y, Morita Y, Hijioka M, Hisano T, Furukawa M

Zinc Deficiency as a General Feature of Cancer: a Review of the Literature

Biol Trace Elem Res. 2023 SEP 2;

Journal Impact Factor 2021: 4.081

PMID: 37658952 (<https://pubmed.ncbi.nlm.nih.gov/37658952>) DOI: 10.1007/s12011-023-03818-6

(<https://doi.org/10.1007/s12011-023-03818-6>) WoS: WOS:001057082500001

(<https://www.webofscience.com/wos/woscc/full-record/WOS:001057082500001>)

#血液学 #多施設共同研究

再発または難治性の末梢性T細胞リンパ腫患者に対する経口HDAC阻害薬ツシジノスタットの第IIb相試験結果についての論文

Rai S, Kim WS, Ando K, **Choi I**, Izutsu K, Tsukamoto N, Yokoyama M, Tsukasaki K, Kuroda J, Ando J, Hidaka M, Koh Y, Shibayama H, Uchida T, Yang DH, Ishitsuka K, Ishizawa K, Kim JS, Lee HG, Minami H, Eom HS,

Kurosawa M, Lee JH, Lee JS, Lee WS, Nagai H, Shindo T, Yoon DH, Yoshida S, Gillings M, Onogi H, Tobinai K

Oral HDAC inhibitor tucidinostat in patients with relapsed or refractory peripheral T-cell lymphoma: phase IIb results

Haematologica. 2023 MAR;108(3):811-821.

Journal Impact Factor 2021: 11.049

PMID: 36200417 (<https://pubmed.ncbi.nlm.nih.gov/36200417>) DOI: 10.3324/haematol.2022.280996

(<https://doi.org/10.3324/haematol.2022.280996>) WoS: WOS:001052101600018

(<https://www.webofscience.com/wos/woscc/full-record/WOS:001052101600018>)

#腫瘍学 #観察研究

上皮成長因子受容体変異陽性非小細胞肺癌患者における手術後の中枢神経系再発の予後への影響についての論文

Okamoto T, Takenaka T, Yamazaki K, Hamatake M, Miura N, Takenoyama M, Kometani T, Ueda H, Kouso H, Yano T

Prognostic Impact of Central Nervous System Recurrence After Surgery in Patients With Epidermal Growth Factor Receptor Mutation-positive Non-small-cell Lung Cancer

Anticancer Res. 2023 AUG;43(8):3543-3551.

Journal Impact Factor 2021: 2.435

PMID: 37500139 (<https://pubmed.ncbi.nlm.nih.gov/37500139>) DOI: 10.21873/anticanres.16532

(<https://doi.org/10.21873/anticanres.16532>) WoS: WOS:001053412600019

(<https://www.webofscience.com/wos/woscc/full-record/WOS:001053412600019>)

#病理学

混合型扁桃体癌における臨床病理学的特徴と遺伝子変異についての論文

Kawata J, **Koga Y**, Noguchi S, Shimada Y, Yamada Y, Yamamoto T, Shindo K, Nakamura M, Oda Y

Clinicopathologic Features and Genetic Alterations in Mixed-Type Ampullary Carcinoma

Mod Pathol. 2023 AUG;36(8)

Journal Impact Factor 2021: 8.209

PMID: 37004749 (<https://pubmed.ncbi.nlm.nih.gov/37004749>) DOI: 10.1016/j.modpat.2023.100181

(<https://doi.org/10.1016/j.modpat.2023.100181>) WoS: WOS:001054214200001

(<https://www.webofscience.com/wos/woscc/full-record/WOS:001054214200001>)

#腫瘍学 #多施設共同研究

アジア人進行 BRAF V600 変異メラノーマ患者に対する全身療法を実臨床で実施：日本における多施設レトロスペクティブ研究 (B-CHECK-RWD研究) についての論文

Namikawa K, Ito T, Yoshikawa S, Yoshino K, Kiniwa Y, Ohe S, Isei T, Takenouchi T, Kato H, Mizuhashi S, Fukushima S, Yamamoto Y, Inozume T, Fujisawa Y, Yamasaki O, Nakamura Y, Asai J, Maekawa T, Funakoshi T, Matsushita S, Nakano E, Oashi K, Kato J, Uhara H, Miyagawa T, **Uchi H**, Hatta N, Tsutsui K, Maeda T, Matsuya T, Yanagisawa H, Muto I, Okumura M, Ogata D, Yamazaki N

Systemic therapy for Asian patients with advanced BRAF V600-mutant melanoma in a real-world setting: A multi-center retrospective study in Japan (B-CHECK-RWD study)

Cancer Med. 2023 SEP;12(17):17967-17980.

Journal Impact Factor 2021: 4.711

PMID: 37584204 (<https://pubmed.ncbi.nlm.nih.gov/37584204>) DOI: 10.1002/cam4.6438

(<https://doi.org/10.1002/cam4.6438>) WoS: WOS:001050661700001

(<https://www.webofscience.com/wos/woscc/full-record/WOS:001050661700001>)

#腫瘍学

EGFR活性化変異を有する未治療転移性非小細胞肺癌患者の循環無細胞DNAに対するラムシルマブ+エルロチニブの影響 (RELAY第3相ランダム化試験) についての論文

Nishio K, Sakai K, Nishio M, **Seto T**, Visseren-Grul C, Carlsen M, Matsui T, Enatsu S, Nakagawa K

Impact of ramucirumab plus erlotinib on circulating cell-free DNA from patients with untreated metastatic non-small cell lung cancer with EGFR-activating mutations (RELAY phase 3 randomized study)

Transl Lung Cancer Res. 2023 AUG;12(8):1702-1716.

Journal Impact Factor 2021: 4.726

PMID: 37691865 (<https://pubmed.ncbi.nlm.nih.gov/37691865>) DOI: 10.21037/tlcr-22-736

(<https://doi.org/10.21037/tlcr-22-736>) WoS: WOS:001049215500001

(<https://www.webofscience.com/wos/woscc/full-record/WOS:001049215500001>)

#複合科学

2018年FIGO病期分類時代の高リスク群における子宮頸癌手術治療：全国調査についての論文

Shigeta S, Shimada M, Tsuji K, Watanabe Z, Tanase Y, Matsuo K, Nakanishi T, **Saito T**, Aoki D, Mikami M

Surgically treated cervical cancer in a high-risk group in the era of the 2018 FIGO staging schema: a nationwide study

Sci Rep. 2023 JUL 25;13(1)

Journal Impact Factor 2021: 4.997

PMID: 37491468 (<https://pubmed.ncbi.nlm.nih.gov/37491468>) DOI: 10.1038/s41598-023-39014-8

(<https://doi.org/10.1038/s41598-023-39014-8>) WoS: WOS:001037011600047

(<https://www.webofscience.com/wos/woscc/full-record/WOS:001037011600047>)

#腫瘍学

I-III期胃癌に対する腹腔鏡下胃切除術を受けた高齢患者における術前栄養評価の予後的意義についての論文

Uehara H, Ota M, Yamamoto M, Nakanoko T, Shin Y, Shiokawa K, Fujimoto Y, Nakashima Y, Sugiyama M, Onishi E, Shimagaki T, Mano Y, Sugimachi K, Morita M, Toh Y

Prognostic Significance of Preoperative Nutritional Assessment in Elderly Patients who Underwent Laparoscopic Gastrectomy for Stage I-III Gastric Cancer

Anticancer Res. 2023 FEB;43(2):893-901.

Journal Impact Factor 2021: 2.435

PMID: 36697095 (<https://pubmed.ncbi.nlm.nih.gov/36697095>) DOI: 10.21873/anticancerres.16232

(<https://doi.org/10.21873/anticancerres.16232>) WoS: WOS:001043563900026

(<https://www.webofscience.com/wos/woscc/full-record/WOS:001043563900026>)

#腫瘍学

閉経後ホルモン状態にあるER陽性HER2陽性進行・転移性乳癌患者におけるフルベストラントと抗HER2療法の併用・非併用：Safari試験データのサブグループ解析 (JBCRG-C06) についての論文

Masuyama M, Masuda N, Kawaguchi H, Yamamoto Y, Saji S, Nakayama T, Aogi K, Anan K, Ohtani S, Sato N, Takano T, **Tokunaga E**, Nakamura S, Hasegawa Y, Hattori M, Fujisawa T, Morita S, Yamaguchi M, Yamashita T, Yotsumoto D, Toi M, Ohno S

Fulvestrant with or without anti-HER2 therapy in patients in a postmenopausal hormonal state and with ER-positive HER2-positive advanced or metastatic breast cancer: A subgroup analysis of data from the Safari study (JBCRG-C06)

Cancer Med. 2023 SEP;12(17):17718-17730.

Journal Impact Factor 2021: 4.711

PMID: 37525895 (<https://pubmed.ncbi.nlm.nih.gov/37525895>) DOI: 10.1002/cam4.6390

(<https://doi.org/10.1002/cam4.6390>) WoS: WOS:001040866300001

(<https://www.webofscience.com/wos/woscc/full-record/WOS:001040866300001>)

#複合科学

膵管腺癌の早期再発の予測因子として術前の簡単なパラメータを用いた新しいスコアリングシステムについての論文
Shimagaki T, Sugimachi K, Mano Y, Tomino T, Onishi E, Nakashima Y, Sugiyama M, Yamamoto M, Morita M, Shimokawa M, Yoshizumi T, Toh Y

A new scoring system with simple preoperative parameters as predictors of early recurrence of pancreatic ductal adenocarcinoma

PLoS One. 2023 JUL 14;18(7)

Journal Impact Factor 2021: 3.752

PMID: 37450554 (<https://pubmed.ncbi.nlm.nih.gov/37450554>) DOI: 10.1371/journal.pone.0288033

(<https://doi.org/10.1371/journal.pone.0288033>) WoS: WOS:001031549800043

(<https://www.webofscience.com/wos/woscc/full-record/WOS:001031549800043>)

#皮膚病学

acralおよびnon-acral皮膚黒色腫における抗PD-1抗体補助療法の術後成績に関連する有害事象：多施設共同観察事後解析研究についての論文

Muto Y, Kambayashi Y, Kato H, Fukushima S, Ito T, Maekawa T, Fujisawa Y, Yoshino K, **Uchi H**, Matsushita S, Yamamoto Y, Amagai R, Ohuchi K, Hashimoto A, Asano Y, Fujimura T

Adverse events associated with postoperative outcomes of adjuvant anti-PD-1 antibody therapy in both acral and non-acral cutaneous melanomas: A multicenter, observational, post hoc analysis study

J Dermatol. 2023 JUL 30;

Journal Impact Factor 2021: 3.468

PMID: 37518979 (<https://pubmed.ncbi.nlm.nih.gov/37518979>) DOI: 10.1111/1346-8138.16912

(<https://doi.org/10.1111/1346-8138.16912>) WoS: WOS:001039397800001

(<https://www.webofscience.com/wos/woscc/full-record/WOS:001039397800001>)

#腫瘍学 #多施設共同研究 #第II相試験

日本人ALK陽性非小細胞肺癌患者におけるブリガチニブ：第2相J-ALTA試験の最終結果についての論文

Yoshida T, Kumagai T, **Toyozawa R**, Katayama R, Nishio M, **Seto T**, Goto K, Yamamoto N, Ohe Y, Kudou K, Asato T, Zhang PK, Nakagawa K

Brigatinib in Japanese patients with ALK-positive non-small-cell lung cancer: Final results of the phase 2 J-ALTA trial

Cancer Sci. 2023 SEP;114(9):3698-3707.

Journal Impact Factor 2021: 6.518

PMID: 37434391 (<https://pubmed.ncbi.nlm.nih.gov/37434391>) DOI: 10.1111/cas.15888

(<https://doi.org/10.1111/cas.15888>) WoS: WOS:001027649500001

(<https://www.webofscience.com/wos/woscc/full-record/WOS:001027649500001>)

#消化器病学 #肝臓学

高齢患者における緊急腹部手術後の嚥下障害予測スコアの開発についての論文

Iguchi T, Mita J, Iseda N, Sasaki S, Harada N, Ninomiya M, **Sugimachi K**, Honboh T, Sadanaga N, Matsuura H

Development of predictive score for postoperative dysphagia after emergency abdominal surgery in patients of advanced age

Ann Gastroent Surg. 2023 JUL 15;

Journal Impact Factor 2021: 3.583

DOI: 10.1002/ags3.12716 (<https://doi.org/10.1002/ags3.12716>) WoS: WOS:001030647800001 (<https://www.webofscience.com/wos/woscc/full-record/WOS:001030647800001>)

#腫瘍学

ヒト上皮成長因子受容体2発現進行・再発子宮癌肉腫に対するトラスツマブ・デルクステカン (NCCH1615) : STATICE試験についての論文

Nishikawa T, Hasegawa K, Matsumoto K, Mori M, Hirashima Y, Takehara K, **Ariyoshi K**, Kato T, Yagishita S, Hamada A, Kawasaki M, Kawashima S, Tomatsuri S, Nagasaka Y, Yoshida H, Machida R, Hirakawa A, Nakamura K, Yonemori K

Trastuzumab Deruxtecan for Human Epidermal Growth Factor Receptor 2-Expressing Advanced or Recurrent Uterine Carcinosarcoma (NCCH1615): The STATICE Trial
J Clin Oncol. 2023 MAY 20;41(15):2789-2799.

Journal Impact Factor 2021: 50.739

PMID: 36977309 (<https://pubmed.ncbi.nlm.nih.gov/36977309>) DOI: 10.1200/JCO.22.02558 (<https://doi.org/10.1200/JCO.22.02558>) WoS: WOS:001003976600019 (<https://www.webofscience.com/wos/woscc/full-record/WOS:001003976600019>)

#腫瘍学

高齢患者を対象とした局所進行胃癌に対するネオアジュバント化学療法としてのS-1+オキサリプラチン併用療法の安全性と有効性を検討する第II相臨床試験についての論文

Ota M, Saeki H, **Uehara H**, Matsuda Y, Tsutsumi S, Kusumoto T, Yasui H, Ubukata Y, Yamaguchi S, Orita H, Izawa N, Kakizoe S, Shimokawa M, Yoshizumi T, Kakeji Y, Mori M, Oki E

Phase II clinical trial to study the safety and efficacy of combined S-1+oxaliplatin therapy as neoadjuvant chemotherapy for locally advanced gastric cancer in older patients
Int J Clin Oncol. 2023 JUN 27;

Journal Impact Factor 2021: 3.85

PMID: 37368093 (<https://pubmed.ncbi.nlm.nih.gov/37368093>) DOI: 10.1007/s10147-023-02373-3 (<https://doi.org/10.1007/s10147-023-02373-3>) WoS: WOS:001015442300001 (<https://www.webofscience.com/wos/woscc/full-record/WOS:001015442300001>)

#腫瘍学

進行EGFRプラス非小細胞肺癌の初回治療において、エルロチニブとベバシズマブの併用・非併用を比較した第II相 JO25567試験のバイオマーカー解析についての論文

Nishio M, Atagi S, Goto K, Hosomi Y, **Seto T**, Hida T, Nakagawa K, Yoshioka H, Nogami N, Maemondo M, Nagase S, Okamoto I, Yamamoto N, Igawa Y, Tajima K, Fukuoka M, Yamamoto N, Nishio K

Biomarker analysis of the phase II JO25567 study comparing erlotinib with or without bevacizumab in first-line advanced EGFR plus non-small-cell lung cancer
Transl Lung Cancer Res. 2023 JUN 13;

Journal Impact Factor 2021: 4.726

PMID: 37425411 (<https://pubmed.ncbi.nlm.nih.gov/37425411>) DOI: 10.21037/tlcr-22-632 (<https://doi.org/10.21037/tlcr-22-632>) WoS: WOS:001013799900001 (<https://www.webofscience.com/wos/woscc/full-record/WOS:001013799900001>)

#複合科学

FOLFIRINOXまたはゲムシタピン+ナブパクリタキセルによる切除不能膵癌において、C反応性蛋白/アルブミン比は最も重要な炎症マーカーであることについての論文

Shirakawa T, Makiyama A, **Shimokawa M**, Otsuka T, Shinohara Y, Koga F, Ueda Y, Nakazawa J, Otsu S, Komori A, Arima S, Fukahori M, Taguchi H, Honda T, Shibuki T, Nio K, Ide Y, Ureshino N, Mizuta T, Mitsugi K, Akashi K, Baba E

C-reactive protein/albumin ratio is the most significant inflammatory marker in unresectable pancreatic cancer treated with FOLFIRINOX or gemcitabine plus nab-paclitaxel
Sci Rep. 2023 MAY 31;13(1)

Journal Impact Factor 2021: 4.997

PMID: 37258608 (<https://pubmed.ncbi.nlm.nih.gov/37258608>) DOI: 10.1038/s41598-023-34962-7 (<https://doi.org/10.1038/s41598-023-34962-7>) WoS: WOS:001001303600029

(<https://www.webofscience.com/wos/woscc/full-record/WOS:001001303600029>)

#腫瘍学

限局期食道神経内分泌癌患者の術後転帰に関連するマイクロRNAについての論文

Okumura T, Fujii T, Terabayashi K, Kojima T, Takeda S, Kashiwada T, Toriyama K, Hijioka S, Miyazaki T, Yamamoto M, Tanabe S, Shirakawa Y, **Furukawa M**, Honma Y, Hoshino I, Nabeya Y, Yamaguchi H, Uemoto S, Shimada Y, Matsubara H, Ozawa S, Makuuchi H, Imamura M

MicroRNAs associated with postoperative outcomes in patients with limited stage neuroendocrine carcinoma of the esophagus

Oncol Lett. 2023 JUL;26(1)

Journal Impact Factor 2021: 3.111

PMID: 37274462 (<https://pubmed.ncbi.nlm.nih.gov/37274462>) DOI: 10.3892/ol.2023.13862

(<https://doi.org/10.3892/ol.2023.13862>) WoS: WOS:001002342200001

(<https://www.webofscience.com/wos/woscc/full-record/WOS:001002342200001>)

#消化器病学 #肝臓学 #レビュー論文

陽子線併用化学放射線療法は食道癌患者の心肺罹患率を減少させる：系統的レビューについての論文

Nonaka T, Kawashiro S, Ishikawa H, Ito Y, Nemoto K, Ishihara R, Oyama T, Oyama T, Kato K, Kato H, Kawakubo H, Kawachi H, Kuribayashi S, Kono K, Kojima T, Takeuchi H, Tsushima T, **Toh Y**, Booka E, Makino T, Matsuda S, Matsubara H, Mano M, Minashi K, Miyazaki T, Muto M, Yamaji T, Yamatsuji T, Yoshida M, Kitagawa Y, Esophageal Canc Practice

Concurrent chemoradiotherapy using proton beams can reduce cardiopulmonary morbidity in esophageal cancer patients: a systematic review

Esophagus. 2023 JUN 17;

Journal Impact Factor 2021: 3.671

PMID: 37328706 (<https://pubmed.ncbi.nlm.nih.gov/37328706>) DOI: 10.1007/s10388-023-01015-x

(<https://doi.org/10.1007/s10388-023-01015-x>) WoS: WOS:001010065500001

(<https://www.webofscience.com/wos/woscc/full-record/WOS:001010065500001>)

#腫瘍学

膵未分化癌の総説：疫学から治療までについての論文

Imaoka H, Ikeda M, Umemoto K, Sunakawa Y, Ueno M, Ueno H, Ozaka M, Kuwahara T, Okano N, Kanai M, **Hisano T**, Suzuki Y, Asagi A, Shioji K, Todaka A, Tsuji K, Ikezawa K, Miki I, Komatsu Y, Akutsu N, Yamashita T, Okuyama H, Furuse J, Nagano H

Comprehensive review of undifferentiated carcinoma of the pancreas: from epidemiology to treatment

Jpn J Clin Oncol. 2023 AUG 30;53(9):764-773.

Journal Impact Factor 2021: 2.925

PMID: 37325968 (<https://pubmed.ncbi.nlm.nih.gov/37325968>) DOI: 10.1093/jjco/hyad062

(<https://doi.org/10.1093/jjco/hyad062>) WoS: WOS:001009965000001

(<https://www.webofscience.com/wos/woscc/full-record/WOS:001009965000001>)

#腫瘍学

非小細胞肺癌患者における一次免疫療法後の生存に対する治療前の予後栄養指標の影響についての論文

Oku Y, Toyokawa G, Wakasu S, **Kinoshita F**, **Takamori S**, Watanabe K, Haratake N, Nagano T, Kosai K, Takada K, Fujimoto A, Higashijima K, Shiraishi Y, Tanaka K, Takeoka H, Okamoto M, Yamashita T, Shimokawa M, **Shoji F**, Yamazaki K, **Okamoto T**, **Seto T**, Ueda H, Takeo S, Nakashima N, Okamoto I, Takenaka T, Yoshizumi T

Impact of the pretreatment prognostic nutritional index on the survival after first-line immunotherapy in non-small-cell lung cancer patients

Cancer Med. 2023 JUL;12(13):14327-14336.

Journal Impact Factor 2021: 4.711

PMID: 37211905 (<https://pubmed.ncbi.nlm.nih.gov/37211905>) DOI: 10.1002/cam4.6110

(<https://doi.org/10.1002/cam4.6110>) WoS: WOS:000993243700001

(<https://www.webofscience.com/wos/woscc/full-record/WOS:000993243700001>)

#ヘルスケア科学 #サービス

精神的実存的苦痛に対する持続的深鎮静法：多施設共同全国調査についての論文

Maeda S, Morita T, Yokomichi N, Imai K, Tsuneto S, Maeda I, Miura T, Ishiki H, **Otani H**, Hatano Y, Mori M
Continuous Deep Sedation for Psycho-Existential Suffering: A Multicenter Nationwide Study
J Palliat Med. 2023 JUN 7;

Journal Impact Factor 2021: 2.947

PMID: 37289183 (<https://pubmed.ncbi.nlm.nih.gov/37289183>) DOI: 10.1089/jpm.2023.0140

(<https://doi.org/10.1089/jpm.2023.0140>) WoS: WOS:001002357400001

(<https://www.webofscience.com/wos/woscc/full-record/WOS:001002357400001>)

#薬理学 #薬学 #症例報告

イホスファミドとアプレピタントの薬物相互作用による脳症の1例についての論文

Sano T, **Setzu N**, Kobayashi E, Kawaib A

A Case of Encephalopathy Caused by Drug Interaction between Ifosfamide and Aprepitant
Yakugaku Zasshi-J Pharm Soc Jpn. 2023;143(6):541-544.

Journal Impact Factor 2021: 0.314

PMID: 37258187 (<https://pubmed.ncbi.nlm.nih.gov/37258187>) DOI: 10.1248/yakushi.22-00186

(<https://doi.org/10.1248/yakushi.22-00186>) WoS: WOS:001000340100009

(<https://www.webofscience.com/wos/woscc/full-record/WOS:001000340100009>)

#消化器病学 #肝臓学 #多施設共同研究

機械学習に基づく膵神経内分泌腫瘍G1/G2の再発予測および特徴解析モデルについての論文

Murakami M, Fujimori N, Nakata K, Nakamura M, Hashimoto S, Kurahara H, Nishihara K, Abe T, Hashigo S, Kugiyama N, Ozawa E, Okamoto K, Ishida Y, Okano K, Takaki R, Shimamatsu Y, Ito T, **Miki M**, Oza N, Yamaguchi D, Yamamoto H, Takedomi H, Kawabe K, Akashi T, Miyahara K, Ohuchida J, Ogura Y, Nakashima Y, Ueki T, Ishigami K, Umakoshi H, Ueda K, Oono T, Ogawa Y

Machine learning-based model for prediction and feature analysis of recurrence in pancreatic neuroendocrine tumors G1/G2

J Gastroenterol. 2023 APR 26;

Journal Impact Factor 2021: 6.772

PMID: 37099152 (<https://pubmed.ncbi.nlm.nih.gov/37099152>) DOI: 10.1007/s00535-023-01987-8

(<https://doi.org/10.1007/s00535-023-01987-8>) WoS: WOS:000989620900001

(<https://www.webofscience.com/wos/woscc/full-record/WOS:000989620900001>)

#腫瘍学

転移性膵癌の二次治療における血清アルブミンとCA19-9によるスコアリングモデル：NAPOLEON試験の結果についての論文

Komori A, Otsu S, **Shimokawa M**, Otsuka T, Koga F, Ueda Y, Nakazawa J, Arima S, Fukahori M, Okabe Y, Makiyama A, Taguchi H, Honda T, Shibuki T, Nio K, Ide Y, Ureshino N, Mizuta T, Shirakawa T, Mitsugi K

Scoring model with serum albumin and CA19-9 for metastatic pancreatic cancer in second-line treatment: results from the NAPOLEON study

Int J Clin Oncol. 2023 AUG;28(8):1073-1081.

Journal Impact Factor 2021: 3.85

PMID: 37209158 (<https://pubmed.ncbi.nlm.nih.gov/37209158>) DOI: 10.1007/s10147-023-02354-6

(<https://doi.org/10.1007/s10147-023-02354-6>) WoS: WOS:000999158700001

(<https://www.webofscience.com/wos/woscc/full-record/WOS:000999158700001>)

#腫瘍学

ステージIIおよびIIIの結腸癌患者における再発リスク決定因子としての分子芽生えシグネチャーの臨床的有用性の向上についての論文

Shinto E, Oki E, Shimokawa M, Yamaguchi S, Ishiguro M, Hasegawa S, Takii Y, Ishida H, Kusumoto T, **Morita M**, Tomita N, Shiozawa M, Tanaka M, Ozawa H, Hashiguchi Y, Ohnuma S, Tada S, Matsushima T, Yamagishi K, Hase K

Enhanced Clinical Utility of Molecular Budding Signature as a Recurrence Risk Determinant in Stage II and III Colon Cancer Patients

Ann Surg Oncol. 2023 MAY 8;

Journal Impact Factor 2021: 4.339

PMID: 37154970 (<https://pubmed.ncbi.nlm.nih.gov/37154970>) DOI: 10.1245/s10434-023-13594-1

(<https://doi.org/10.1245/s10434-023-13594-1>) WoS: WOS:000984641000001

(<https://www.webofscience.com/wos/woscc/full-record/WOS:000984641000001>)

#生物物理学

成人T細胞白血病/リンパ腫患者におけるHLA不適合非血縁者移植の影響についての論文

Inoue Y, Morishima S, Kato K, Ito A, Nakano N, Kuriyama T, Kawakita T, Mori Y, **Suehiro Y**, Itonaga H, Miyazaki Y, Imada K, Tomori S, Kanda J, Ichinohe T, Atsuta Y, Fukuda T, Yoshimitsu M, ATL Working Grp Japanese Soc

Impact of HLA-mismatched unrelated transplantation in patients with adult T-cell leukemia/lymphoma

Bone Marrow Transplant. 2023 SEP;58(9):980-990.

Journal Impact Factor 2021: 5.174

PMID: 37173417 (<https://pubmed.ncbi.nlm.nih.gov/37173417>) DOI: 10.1038/s41409-023-02002-7

(<https://doi.org/10.1038/s41409-023-02002-7>) WoS: WOS:000986328400001

(<https://www.webofscience.com/wos/woscc/full-record/WOS:000986328400001>)

#腫瘍学 #多施設共同研究

術後再発EGFR変異非小細胞肺癌に根治的局所療法は有効か？についての論文

Takenaka T, Yano T, Yamazaki K, **Okamoto T**, Hamatake M, Takamori S, Kohno M, Miura N, Shimokawa M, Yoshizumi T, Kyushu Univ Lung Surg Study Grp

Is radical local therapy effective in postoperative recurrent EGFR-mutated non-small cell lung cancer?

Thorac Cancer. 2023 JUN;14(18):1660-1667.

Journal Impact Factor 2021: 3.223

PMID: 37143400 (<https://pubmed.ncbi.nlm.nih.gov/37143400>) DOI: 10.1111/1759-7714.14911

(<https://doi.org/10.1111/1759-7714.14911>) WoS: WOS:000982106400001

(<https://www.webofscience.com/wos/woscc/full-record/WOS:000982106400001>)

#腫瘍学

FOLFIRINOXまたはゲムシタピン+Nab-パクリタキセルで治療された切除不能膵癌に対する転換手術についての論文

Ide Y, Otsuka T, **Shimokawa M**, Koga F, Ueda Y, Nakazawa J, Komori A, Otsu S, Arima S, Fukahori M, Makiyama A, Shinohara Y, Ueno S, Taguchi H, Honda T, Shibuki T, Nio K, Ureshino N, Mizuta T, Mitsugi K, Shirakawa T

Conversion Surgery for Unresectable Pancreatic Cancer Treated With FOLFIRINOX or Gemcitabine Plus Nab-paclitaxel

Anticancer Res. 2023 APR;43(4):1817-1826.

Journal Impact Factor 2021: 2.435

PMID: 36974805 (<https://pubmed.ncbi.nlm.nih.gov/36974805>) DOI: 10.21873/anticancerres.16335

(<https://doi.org/10.21873/anticancerres.16335>) WoS: WOS:000990845600018

(<https://www.webofscience.com/wos/woscc/full-record/WOS:000990845600018>)

#腫瘍学 #レビュー論文

癌遺伝子中毒非小細胞肺癌における腫瘍の可塑性と治療抵抗性：前臨床観察から臨床的意義までについての論文

Toyokawa G, Bersani F, Bironzo P, Picca F, Tabbò F, Haratake N, Takenaka T, **Seto T**, Yoshizumi T, Novello S, Scagliotti GV, Taulli R

Tumor plasticity and therapeutic resistance in oncogene-addicted non-small cell lung cancer: from preclinical observations to clinical implications

Crit Rev Oncol/Hematol. 2023 APR;184

Journal Impact Factor 2021: 6.625

PMID: 36925092 (<https://pubmed.ncbi.nlm.nih.gov/36925092>) DOI: 10.1016/j.critrevonc.2023.103966

(<https://doi.org/10.1016/j.critrevonc.2023.103966>) WoS: WOS:000994313900001

(<https://www.webofscience.com/wos/woscc/full-record/WOS:000994313900001>)

#心臓 #循環器系

下行性壊死性縦隔炎に対する胸腔鏡手術の有効性についての論文

Tanaka Y, Maniwa Y, Sugio K, **Okamoto T**, Nibu KI, Omori T, Endo S, Kuwano H, Chida M, **Toh Y**, Okada M, Shiotani A, Yoshino I

The efficacy of thoracoscopic surgery for descending necrotizing mediastinitis

Interdiscip Cardiovasc Thorac Surg. 2023 APR 3;36(4)

PMID: 37018143 (<https://pubmed.ncbi.nlm.nih.gov/37018143>) DOI: 10.1093/icvts/ivad053

(<https://doi.org/10.1093/icvts/ivad053>) WoS: WOS:000979716100001

(<https://www.webofscience.com/wos/woscc/full-record/WOS:000979716100001>)

#腫瘍学 #第II相試験 #多施設共同研究

抗EGFR抗体治療抵抗性のRAS野生型mCRC患者を対象としたトリフルリジン/ティピラシルとセツキシマブ再治療の併用第II相試験：WJOG8916G試験についての論文

Izawa N, Masuishi T, Takahashi N, Shoji H, Yamamoto Y, Matsumoto T, Sugiyama K, Kajiwara T, Kawakami K, Aomatsu N, Kondoh C, Kawakami H, Takegawa N, **Esaki T**, Shimokawa M, Nishio K, Narita Y, Hara H, Sunakawa Y, Boku N, Moriwaki T, Nakajima TE, Muro K

A Phase II Trial of Trifluridine/Tipiracil in Combination with Cetuximab Rechallenge in Patients with RAS Wild-Type mCRC Refractory to Prior Anti-EGFR Antibodies: WJOG8916G Trial

Target Oncol. 2023 MAY;18(3):369-381.

Journal Impact Factor 2021: 4.897

PMID: 37148491 (<https://pubmed.ncbi.nlm.nih.gov/37148491>) DOI: 10.1007/s11523-023-00963-9

(<https://doi.org/10.1007/s11523-023-00963-9>) WoS: WOS:000982961200001

(<https://www.webofscience.com/wos/woscc/full-record/WOS:000982961200001>)

#微生物学

CTL応答が低下した自然STLV-1感染ニホンザルにおいて、短期培養自己PBMCによるワクチン接種がSTLV-1特異的CTLを効率的に活性化したことについての論文

Hasegawa A, Murata M, Fujikawa T, Katagiri K, Nagano Y, Masuda T, Kuramitsu M, Nakajima S, Fujisawa JI, Okuma K, Grover P, Kidiga M, Akari H, Kannagi M

Vaccination with short-term-cultured autologous PBMCs efficiently activated STLV-1-specific CTLs in naturally STLV-1-infected Japanese monkeys with impaired CTL responses

PLoS Pathog. 2023 FEB;19(2)

Journal Impact Factor 2021: 7.464

PMID: 36730466 (<https://pubmed.ncbi.nlm.nih.gov/36730466>) DOI: 10.1371/journal.ppat.1011104

(<https://doi.org/10.1371/journal.ppat.1011104>) WoS: WOS:000975429900002

(<https://www.webofscience.com/wos/woscc/full-record/WOS:000975429900002>)

#腫瘍学 #多施設共同研究

膵臓転移に対する膵切除術の生存への影響：後方視的多施設研究についての論文

Kinoshita S, Yamashita Y, Kitano Y, Hayashi H, **Sugimachi K**, Nishizaki T, Fukuzawa K, Kajiyama K, Miyanari N, Yoshizumi T, Takamori H, Baba H

Survival impact of pancreatic resection for metastases in the pancreas: A retrospective multi-center study

Surg Oncol-Oxf. 2023 JUN;48

Journal Impact Factor 2021: 2.388

PMID: 37043926 (<https://pubmed.ncbi.nlm.nih.gov/37043926>) DOI: 10.1016/j.suronc.2023.101942

(<https://doi.org/10.1016/j.suronc.2023.101942>) WoS: WOS:000982096900001

(<https://www.webofscience.com/wos/woscc/full-record/WOS:000982096900001>)

#医学 #研究 #実験

日本における上咽頭がんに対する免疫チェックポイント阻害剤の実臨床での使用状況についての論文

Manako T, Yasumatsu R, **Nakano T**, Matsuo M, Takeuchi T, Taura M, Tamae A, Yamauchi M, **Masuda M**, **Taguchi K**, Nakagawa T

**Immune Checkpoint Inhibitors for Nasopharyngeal Carcinoma in a Real-world Setting in Japan
In Vivo.** 2023 MAR-APR;37(2):747-755.

Journal Impact Factor 2021: 2.406

PMID: 36881083 (<https://pubmed.ncbi.nlm.nih.gov/36881083>) DOI: 10.21873/invivo.13137

(<https://doi.org/10.21873/invivo.13137>) WoS: WOS:000961578500030

(<https://www.webofscience.com/wos/woscc/full-record/WOS:000961578500030>)

#腫瘍学

切除された病理学的ステージIAの肺腺癌における非浸潤領域の予後への影響についての論文

Kinoshita F, Shimokawa M, Takenaka T, Okamoto T, Taguchi K, Oda Y, Yoshizumi T

Prognostic impact of noninvasive areas in resected pathological stage IA lung adenocarcinoma

Thorac Cancer. 2023 JUN;14(18):1651-1659.

Journal Impact Factor 2021: 3.223

PMID: 37105937 (<https://pubmed.ncbi.nlm.nih.gov/37105937>) DOI: 10.1111/1759-7714.14910

(<https://doi.org/10.1111/1759-7714.14910>) WoS: WOS:000979794600001

(<https://www.webofscience.com/wos/woscc/full-record/WOS:000979794600001>)

#血液学

再発難治性急性リンパ芽球性白血病の小児患者を対象としたボルテゾミブ併用化学療法の第2相試験についての論文

Miyagawa N, Goto H, Ogawa A, Kikuta A, Kosaka Y, Sekimizu M, Tomizawa D, Toyoda H, Hiramatsu H, Hara J,

Mochizuki S, Nakayama H, Yoshimura K, Iijima-Yamashita Y, Sanada M, Ogawa C

Phase 2 study of combination chemotherapy with bortezomib in children with relapsed and refractory acute lymphoblastic leukemia

Int J Hematol. 2023 AUG;118(2):267-276.

Journal Impact Factor 2021: 2.324

PMID: 37127801 (<https://pubmed.ncbi.nlm.nih.gov/37127801>) DOI: 10.1007/s12185-023-03609-8

(<https://doi.org/10.1007/s12185-023-03609-8>) WoS: WOS:000978823600001

(<https://www.webofscience.com/wos/woscc/full-record/WOS:000978823600001>)

#腫瘍学

高齢の進行性非小細胞肺癌患者におけるプラチナ製剤ダブルト併用療法の臨床的有用性：国立病院機構による前向き多施設共同研究についての論文

Shimokawa M, Kanazu M, Saito R, Mori M, Tamura A, Okano Y, Fujita Y, Endo T, Motegi M, Takata S, Kita T,

Sukoh N, Mizuki F, Takenoyama M, Atagi S

Clinical benefit of platinum doublet combination therapy in older adults with advanced non-small cell lung cancer: A prospective multicenter study by the National Hospital Organization in Japan

Thorac Cancer. 2023 JUN;14(17):1597-1605.

Journal Impact Factor 2021: 3.223

PMID: 37073452 (<https://pubmed.ncbi.nlm.nih.gov/37073452>) DOI: 10.1111/1759-7714.14904

(<https://doi.org/10.1111/1759-7714.14904>) WoS: WOS:000974326100001

(<https://www.webofscience.com/wos/woscc/full-record/WOS:000974326100001>)

#腫瘍学

WT1ペプチドワクチンに対する免疫反応性は高齢の急性骨髄性白血病患者の予後と関連する：HLAクラスII結合WT1ポリペプチドOCV-501の無作為化第II相試験のフォローアップ試験についての論文

Naoe T, Saito A, Hosono N, Kasahara S, Muto H, Hatano K, Ogura M, Masunari T, Tanaka M, Usuki K, Ishikawa

Y, Ando K, Kondo Y, Takagi Y, Takada S, Ishikawa M, Choi I, Sano A, Nagai H

Immunoreactivity to WT1 peptide vaccine is associated with prognosis in elderly patients with acute myeloid leukemia: follow-up study of randomized phase II trial of OCV-501, an HLA class II-binding WT1 polypeptide

Cancer Immunol Immunother. 2023 AUG;72(8):2865-2871.

Journal Impact Factor 2021: 6.63

PMID: 37093243 (<https://pubmed.ncbi.nlm.nih.gov/37093243>) DOI: 10.1007/s00262-023-03432-4

(<https://doi.org/10.1007/s00262-023-03432-4>) WoS: WOS:000974758000001

(<https://www.webofscience.com/wos/woscc/full-record/WOS:000974758000001>)

#腫瘍学

日本人進行胃がん・胃食道接合部がん患者に対するペムブロリズマブ単剤療法の有効性についての論文

Muro K, Shitara K, Yamaguchi K, Yoshikawa T, Satake H, Hara H, Sugimoto N, Machida N, Goto M, Kawakami H, Amagai K, Omuro Y, **Esaki T**, Hironaka S, Nishina T, Komatsu Y, Matsubara H, Shiratori S, Han SR, Satoh T, Ohtsu A

Efficacy of Pembrolizumab Monotherapy in Japanese Patients with Advanced Gastric or Gastroesophageal Junction Cancer

J Gastrointest Cancer. 2023 SEP;54(3):951-961.

Journal Impact Factor 2021: N/A

PMID: 37037952 (<https://pubmed.ncbi.nlm.nih.gov/37037952>) DOI: 10.1007/s12029-023-00920-9

(<https://doi.org/10.1007/s12029-023-00920-9>) WoS: WOS:000966614800001

(<https://www.webofscience.com/wos/woscc/full-record/WOS:000966614800001>)

#血液学

再発・難治性の低悪性度B細胞性非ホジキンリンパ腫に対するイットリウム-90イブリツモマブ・ティウセタン治療のリアルワールドデータ：J3Zi試験についての論文

Choi I, Okada M, Ito T

Real-world data from yttrium-90 ibritumomab tiuxetan treatment of relapsed or refractory indolent B-cell non-Hodgkin's lymphoma: J3Zi Study

Ann Hematol. 2023 MAR 30;

Journal Impact Factor 2021: 4.03

PMID: 36995403 (<https://pubmed.ncbi.nlm.nih.gov/36995403>) DOI: 10.1007/s00277-023-05157-x

(<https://doi.org/10.1007/s00277-023-05157-x>) WoS: WOS:000960164000002

(<https://www.webofscience.com/wos/woscc/full-record/WOS:000960164000002>)

#腫瘍学

FIGHT-102：日本人の進行性悪性腫瘍患者を対象としたペミガチニブの第1相試験についての論文

Fujiwara Y, Kuboki Y, **Furukawa M**, Mizuno N, Hara H, Ioka T, Ueno M, Takahashi Y, Takahashi S, Takeuchi S, Lihou C, Ji T, Tian CW, Shimizu T

FIGHT-102: A phase 1 study of pemigatinib in Japanese patients with advanced malignancies
Cancer Med. 2023 MAY;12(9):10597-10611.

Journal Impact Factor 2021: 4.711

PMID: 37000035 (<https://pubmed.ncbi.nlm.nih.gov/37000035>) DOI: 10.1002/cam4.5798

(<https://doi.org/10.1002/cam4.5798>) WoS: WOS:000961599600001

(<https://www.webofscience.com/wos/woscc/full-record/WOS:000961599600001>)

#腫瘍学

フッ素化ピリミジンの創薬研究の系譜：藤井節郎教授が達成した業績の年代記についての論文

Maehara Y, Oki E, Ota M, Harimoto N, Ando K, Nakanishi R, Kawazoe T, Fujimoto Y, Nonaka K, Kitao H, Iimori M, Makino K, Takeuchi T, Sagara T, Miyadera K, Matsuoka K, Tsukihara H, Kataoka Y, Wakasa T, Ochiwa H, Kamahori Y, **Tokunaga E**, Saeki H, Yoshizumi T, Kakeji Y, Shirabe K, Baba H, Shimada M

Lineage of drug discovery research on fluorinated pyrimidines: chronicle of the achievements accomplished by Professor Setsuro Fujii

Int J Clin Oncol. 2023 MAY;28(5):613-624.

Journal Impact Factor 2021: 3.85

PMID: 36961615 (<https://pubmed.ncbi.nlm.nih.gov/36961615>) DOI: 10.1007/s10147-023-02326-w

(<https://doi.org/10.1007/s10147-023-02326-w>) WoS: WOS:000955751600001

(<https://www.webofscience.com/wos/woscc/full-record/WOS:000955751600001>)

#消化器病学 #肝臓学

食道癌診療ガイドライン2022 日本食道学会編：その1についての論文

Kitagawa Y, Ishihara R, Ishikawa H, Ito Y, Oyama T, Oyama T, Kato K, Kato H, Kawakubo H, Kawachi H, Kuribayashi S, Kono K, Kojima T, Takeuchi H, Tsushima T, **Toh Y**, Nemoto K, Booka E, Makino T, Matsuda S, Matsubara H, Mano M, Minashi K, Miyazaki T, Muto M, Yamaji T, Yamatsuji T, Yoshida M

Esophageal cancer practice guidelines 2022 edited by the Japan esophageal society: part 1 Esophagus. 2023 JUL;20(3):343-372.

Journal Impact Factor 2021: 3.671

PMID: 36933136 (<https://pubmed.ncbi.nlm.nih.gov/36933136>) DOI: 10.1007/s10388-023-00993-2 (<https://doi.org/10.1007/s10388-023-00993-2>) WoS: WOS:000953752400002 (<https://www.webofscience.com/wos/woscc/full-record/WOS:000953752400002>)

#心臓 #循環器系

骨格筋面積は非小細胞肺がんの3剤併用療法後の転帰を予測することについての論文

Watanabe K, Kinoshita F, Takenaka T, Nagano T, Oku Y, Kosai K, Ono Y, Haratake N, Kohno M, Kamitani T, Yoshitake T, Okamoto T, Shimokawa M, Ishigami K, Yoshizumi T

Skeletal muscle area predicts the outcomes of non-small-cell lung cancer after trimodality therapy Interdiscip Cardiovasc Thorac Surg. 2023 FEB 6;36(2)

PMID: 36847675 (<https://pubmed.ncbi.nlm.nih.gov/36847675>) DOI: 10.1093/icvts/ivad020 (<https://doi.org/10.1093/icvts/ivad020>) WoS: WOS:000946168700010 (<https://www.webofscience.com/wos/woscc/full-record/WOS:000946168700010>)

#腫瘍学

EGFR遺伝子変異陽性の非小細胞肺がんに対するDS-1205cとゲフィチニブの併用療法に関する第1相試験についての論文

Goto K, Shiraishi Y, Murakami H, Horinouchi H, Toyozawa R, Takeda M, Uno M, Crawford N, McGill J, Jimbo T, Ishigami M, Takayama G, Nakayama S, Ohwada S, Nishio M

Phase 1 study of DS-1205c combined with gefitinib for EGFR mutation-positive non-small cell lung cancer

Cancer Med. 2023 MAR;12(6):7090-7104.

Journal Impact Factor 2021: 4.711

PMID: 36621830 (<https://pubmed.ncbi.nlm.nih.gov/36621830>) DOI: 10.1002/cam4.5508 (<https://doi.org/10.1002/cam4.5508>) WoS: WOS:000911164500001 (<https://www.webofscience.com/wos/woscc/full-record/WOS:000911164500001>)

#放射線学 #核医学 #医用画像

骨盤癌の画像誘導放射線治療におけるコーンビームCTの成人用メッシュ型基準計算ファントムを用いた線量推定法についての論文

Cumur C, Fujibuchi T, Arakawa H, Hamada K

Dose estimation for cone-beam computed tomography in image-guided radiation therapy for pelvic cancer using adult mesh-type reference computational phantoms

Radiol Phys Technol. 2023 JUN;16(2):203-211.

Journal Impact Factor 2021: N/A

PMID: 36877400 (<https://pubmed.ncbi.nlm.nih.gov/36877400>) DOI: 10.1007/s12194-023-00708-3 (<https://doi.org/10.1007/s12194-023-00708-3>) WoS: WOS:000943910300002 (<https://www.webofscience.com/wos/woscc/full-record/WOS:000943910300002>)

#腫瘍学

非小細胞肺がんにおけるC反応性蛋白対リンパ球比の予後への影響：傾向スコアマッチング法による解析についての論文

Nagano T, Kinoshita F, Hashinokuchi A, Matsudo K, Watanabe K, Takamori S, Kohno M, Miura N, Shimokawa M, Takenaka T, Yoshizumi T

Prognostic Impact of C-Reactive Protein-to-Lymphocyte Ratio in Non-small Cell Lung Cancer: A Propensity Score-Matching Analysis

Ann Surg Oncol. 2023 FEB 27;

Journal Impact Factor 2021: 4.339

PMID: 36847957 (<https://pubmed.ncbi.nlm.nih.gov/36847957>) DOI: 10.1245/s10434-023-13250-8 (<https://doi.org/10.1245/s10434-023-13250-8>) WoS: WOS:000941087500003 (<https://www.webofscience.com/wos/woscc/full-record/WOS:000941087500003>)

#腫瘍学

非小細胞肺癌患者における免疫チェックポイント阻害薬とプラチナ製剤の併用化学療法による免疫関連有害事象を示すリスクファクター：多施設共同レトロスペクティブスタディについての論文

Fujimoto A, Koutake Y, **Hisamatsu D**, Ookubo N, Yabuuchi Y, Kamimura G, Kai T, Kozono A, Ootsu T, Suzuki H, Matsuo K, Kuwahara K, Oiwan Y, Nagata Y, Tanimoto K, Sato E, Suenaga M, Uehara T, Ikari A, Endo S, Hiraki Y, Kawamata Y

Risk factors indicating immune-related adverse events with combination chemotherapy with immune checkpoint inhibitors and platinum agents in patients with non-small cell lung cancer: a multicenter retrospective study

Cancer Immunol Immunother. 2023 JUL;72(7):2169-2178.

Journal Impact Factor 2021: 6.63

PMID: 36849845 (<https://pubmed.ncbi.nlm.nih.gov/36849845>) DOI: 10.1007/s00262-023-03408-4

(<https://doi.org/10.1007/s00262-023-03408-4>) WoS: WOS:000941111500001

(<https://www.webofscience.com/wos/woscc/full-record/WOS:000941111500001>)

#腫瘍学

膵臓癌における転移部位別循環腫瘍DNA解析の臨床的意義についての論文

Umamoto K, Sunakawa Y, Ueno M, **Furukawa M**, Mizuno N, Sudo K, Kawamoto Y, Kajiwara T, Ohtsubo K, Okano N, Matsushashi N, Itoh S, Matsumoto T, Shimizu S, Otsuru T, Hasegawa H, Okuyama H, Ohama H, Moriwaki T, Ohta T, Odegaard JI, Nakamura Y, Bando H, Yoshino T, Ikeda M, Morizane C

Clinical significance of circulating-tumour DNA analysis by metastatic sites in pancreatic cancer
Br J Cancer. 2023 APR 12;128(8):1603-1608.

Journal Impact Factor 2021: 9.082

PMID: 36782009 (<https://pubmed.ncbi.nlm.nih.gov/36782009>) DOI: 10.1038/s41416-023-02189-y

(<https://doi.org/10.1038/s41416-023-02189-y>) WoS: WOS:000940471600001

(<https://www.webofscience.com/wos/woscc/full-record/WOS:000940471600001>)

#医学 #一般医療 #内科学

がん患者の血清亜鉛濃度は低く、肝硬変を合併すると上昇しにくい。レトロスペクティブスタディについての論文
Sugimoto R, Tanaka Y, Senju T, Morita Y, Lee L, Hijioka M, Hisano T, Furukawa M
Serum zinc levels in cancer patients are low and difficult to elevate when complicated by liver cirrhosis: A retrospective study

Medicine (Baltimore). 2023 JAN 20;102(3)

Journal Impact Factor 2021: 1.817

PMID: 36701704 (<https://pubmed.ncbi.nlm.nih.gov/36701704>) DOI: 10.1097/MD.00000000000032703

(<https://doi.org/10.1097/MD.00000000000032703>) WoS: WOS:000928222100008

(<https://www.webofscience.com/wos/woscc/full-record/WOS:000928222100008>)

#血液学

ダウン症のない急性巨核芽球性白血病の小児に対する造血細胞移植についての論文

Hama A, Taga T, Tomizawa D, Muramatsu H, Hasegawa D, Adachi S, Yoshida N, **Noguchi M**, Sato M, Okada K, Koh K, Mitsui T, Takahashi Y, Miyamura T, Hashii Y, Kato K, Atsuta Y, Okamoto Y

Haematopoietic cell transplantation for children with acute megakaryoblastic leukaemia without Down syndrome

Br J Haematol. 2023 MAY;201(4):747-756.

Journal Impact Factor 2021: 8.615

PMID: 36786154 (<https://pubmed.ncbi.nlm.nih.gov/36786154>) DOI: 10.1111/bjh.18691

(<https://doi.org/10.1111/bjh.18691>) WoS: WOS:000933241600001

(<https://www.webofscience.com/wos/woscc/full-record/WOS:000933241600001>)

#腫瘍学

JGOG2046：臨床的に診断されたFIGOステージIVbの子宮内膜がんに対するネオアジュバント化学療法とデバルキング手術のフィージビリティ・スタディについての論文

Nakanishi T, **Saito T**, Aoki D, Watanabe Y, Ushijima K, Takano M, Sugiyama T, Yaegashi N, Takehara K

JGOG2046: a feasibility study of neoadjuvant chemotherapy followed by debulking surgery for clinically diagnosed FIGO stage IVb endometrial cancer

Int J Clin Oncol. 2023 MAR;28(3):436-444.

Journal Impact Factor 2021: 3.85

PMID: 36729215 (<https://pubmed.ncbi.nlm.nih.gov/36729215>) DOI: 10.1007/s10147-022-02284-9
(<https://doi.org/10.1007/s10147-022-02284-9>) WoS: WOS:000924708700001
(<https://www.webofscience.com/wos/woscc/full-record/WOS:000924708700001>)

#腫瘍学

進行がん患者における味覚・嗅覚障害が食事摂取量および悪液質関連QOLに及ぼす影響についての論文

Otani H, Amano K, Morita T, Miura T, Mori N, Tatara R, Kessoku T, Matsuda Y, Tagami K, Mori M, Taniyama T, Nakajima N, Nakanishi E, Kako J, Shirado AN, Yokomichi N, Miyashita M

Impact of taste/smell disturbances on dietary intakes and cachexia-related quality of life in patients with advanced cancer

Support Care Cancer. 2023 FEB;31(2)

Journal Impact Factor 2021: 3.359

PMID: 36715776 (<https://pubmed.ncbi.nlm.nih.gov/36715776>) DOI: 10.1007/s00520-023-07598-6
(<https://doi.org/10.1007/s00520-023-07598-6>) WoS: WOS:000923921000001
(<https://www.webofscience.com/wos/woscc/full-record/WOS:000923921000001>)

#遺伝学 #遺伝

血漿活性化乳酸リンゲル液のがん細胞に対する影響：遺伝毒性評価についての論文

Liu Y, Nakatsu Y, Tanaka H, Koga K, Ishikawa K, Shiratani M, Hori M

Effects of plasma-activated Ringer's lactate solution on cancer cells: evaluation of genotoxicity

Gene Environ. 2023 JAN 13;45(1)

Journal Impact Factor 2021: 2.627

PMID: 36639786 (<https://pubmed.ncbi.nlm.nih.gov/36639786>) DOI: 10.1186/s41021-023-00260-x
(<https://doi.org/10.1186/s41021-023-00260-x>) WoS: WOS:000915837600001
(<https://www.webofscience.com/wos/woscc/full-record/WOS:000915837600001>)

#腫瘍学

胸腺癌患者を対象としたニボルマブの第II相試験における包括的なバイオマーカー分析についての論文

Katsuya Y, Kitano S, Yamashita M, Ouchi M, Yagishita S, Hamada A, Nakamura H, Hosoda F, Shibata T, Motoi N, Nakayama T, **Seto T**, Umemura S, Hosomi Y, Satouchi M, Nishio M, Kozuki T, Hida T, Ohe Y, Horinouchi H

Comprehensive biomarker analysis from phase II study of nivolumab in patients with thymic carcinoma

Front Oncol. 2023 JAN 9;12

Journal Impact Factor 2021: 5.738

PMID: 36698400 (<https://pubmed.ncbi.nlm.nih.gov/36698400>) DOI: 10.3389/fonc.2022.966527
(<https://doi.org/10.3389/fonc.2022.966527>) WoS: WOS:000916893200001
(<https://www.webofscience.com/wos/woscc/full-record/WOS:000916893200001>)

#腫瘍学

エクソソーム分泌を制御するRab27bは胃癌の腹膜転移と関連することについての論文

Nambara S, Masuda T, Hirose K, Hu QJ, Tobo T, Ozato Y, Kurashige J, Hiraki Y, Hisamatsu Y, Iguchi T, **Sugimachi K**, Oki E, Yoshizumi T, Mimori K

Rab27b, a Regulator of Exosome Secretion, Is Associated With Peritoneal Metastases in Gastric Cancer

Cancer Genomics Proteomics. 2023 JAN-FEB;20(1):30-39.

Journal Impact Factor 2021: 3.395

PMID: 36581340 (<https://pubmed.ncbi.nlm.nih.gov/36581340>) DOI: 10.21873/cgp.20362
(<https://doi.org/10.21873/cgp.20362>) WoS: WOS:000907315600004
(<https://www.webofscience.com/wos/woscc/full-record/WOS:000907315600004>)

#腫瘍学 #ランダム化比較試験 #第II相試験

進行・再発乳癌に対するエンチノスタット+エキセメスタンの有効性と探索的バイオマーカー解析：第II相ランダム化比較試験についての論文

Iwata H, Nakamura R, Masuda N, Yamashita T, Yamamoto Y, Kobayashi K, Tsurutani J, Iwasa T, Yonemori K, Tamura K, Aruga T, **Tokunaga E**, Kaneko K, Lee MJ, Yuno A, Kawabata A, Seike T, Kaneda A, Nishimura Y, Trepel JB, Saji S

Efficacy and exploratory biomarker analysis of entinostat plus exemestane in advanced or recurrent breast cancer: phase II randomized controlled trial

Jpn J Clin Oncol. 2023 JAN 6;53(1):4-15.

Journal Impact Factor 2021: 2.925

PMID: 36398439 (<https://pubmed.ncbi.nlm.nih.gov/36398439>) DOI: 10.1093/jjco/hyac166

(<https://doi.org/10.1093/jjco/hyac166>) WoS: WOS:000890952500001

(<https://www.webofscience.com/wos/woscc/full-record/WOS:000890952500001>)

10月～3月

#泌尿器学 #腎臓学

抗がん剤治療中の腎障害管理に関する臨床診療ガイドラインのクリニカルクエストとグッドプラクティスステートメント 2022年についての論文

Yanagita M, Muto S, Nishiyama H, Ando Y, Hirata S, Doi K, Fujiwara Y, Hanafusa N, Hatta T, Hoshino J, Ichioka S, Inoue T, Ishikura K, Kato T, Kitamura H, Kobayashi Y, Koizumi Y, Kondoh C, Matsubara T, Matsubara K, Matsumoto K, Okuda Y, **Okumura Y**, Sakaida E, Shibagaki Y, Shimodaira H, Takano N, Uchida A, Yakushijin K, Yamamoto T, Yamamoto K, Yasuda Y, Oya M, Okada H, Nangaku M, Kashihara N

Clinical questions and good practice statements of clinical practice guidelines for management of kidney injury during anticancer drug therapy 2022

Clin Exp Nephrol. 2023 OCT 25;

Journal Impact Factor 2021: 2.621

PMID: 37878114 (<https://pubmed.ncbi.nlm.nih.gov/37878114>) DOI: 10.1007/s10157-023-02415-0

(<https://doi.org/10.1007/s10157-023-02415-0>) WoS: WOS:001093956500001

(<https://www.webofscience.com/wos/woscc/full-record/WOS:001093956500001>)

#腫瘍学 #多施設共同研究

成人頭頸部傍髄膜横紋筋肉腫のサルベージ療法を含む生存成績：日本の多施設後方視的研究についての論文

Tsuchihashi K, Ito M, Arita S, Kusaba H, Kusano W, Matsumura T, Kitazono T, Ueno S, Taguchi R, Yoshihiro T, Doi Y, Arimizu K, Ohmura H, Kajitani T, Nio K, Nakano M, Oshima K, Tamura S, Shirakawa T, Shimokawa H, Uchino K, **Hanamura F**, **Okumura Y**, **Komoda M**, Isobe T, Ariyama H, **Esaki T**, Hashimoto K, Komune N, Matsuo M, Matsumoto K, Asai K, Yoshitake T, Yamamoto H, Oda Y, Akashi K, Baba E

Survival outcomes including salvage therapy of adult head and neck para-meningeal rhabdomyosarcoma: a multicenter retrospective study from Japan

BMC Cancer. 2023 OCT 31;23(1)

Journal Impact Factor 2021: 4.638

PMID: 37904096 (<https://pubmed.ncbi.nlm.nih.gov/37904096>) DOI: 10.1186/s12885-023-11528-4

(<https://doi.org/10.1186/s12885-023-11528-4>) WoS: WOS:001093964100001

(<https://www.webofscience.com/wos/woscc/full-record/WOS:001093964100001>)

#複合科学

REGOTAS試験の転移性大腸癌患者におけるトリフルリジン/チピラシル誘発有害事象のリスク因子としての腎障害についての論文

Shiroyama M, Fukuoka S, Masuishi T, Takashima A, Kumekawa Y, Kajiwara T, Yamazaki K, Shimada Y, **Esaki T**, Makiyama A, Moriwaki T

Renal impairment as a risk factor for trifluridine/tipiracil-induced adverse events in metastatic colorectal cancer patients from the REGOTAS study

Sci Rep. 2023 OCT 20;13(1)

Journal Impact Factor 2021: 4.997

PMID: 37863951 (<https://pubmed.ncbi.nlm.nih.gov/37863951>) DOI: 10.1038/s41598-023-45244-7

(<https://doi.org/10.1038/s41598-023-45244-7>) WoS: WOS:001087596300006

(<https://www.webofscience.com/wos/woscc/full-record/WOS:001087596300006>)

#医学 #一般医療 #内科学

変異KRAS G12Cを有する難治性大腸癌に対するソトラシブとパニツムマブの併用療法についての論文

Fakih MG, Salvatore L, **Esaki T**, Modest DP, Lopez-Bravo DP, Taieb J, Karamouzis MV, Ruiz-Garcia E, Kim TW, Kuboki Y, Meriggi F, Cunningham D, Yeh KH, Chan EMY, Chao JS, Saportas Y, Tran Q, Cremolini C, Pietrantonio F

Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C

N Engl J Med. 2023 OCT 22;

Journal Impact Factor 2021: 176.082

PMID: 37870968 (<https://pubmed.ncbi.nlm.nih.gov/37870968>) DOI: 10.1056/NEJMoa2308795

(<https://doi.org/10.1056/NEJMoa2308795>) WoS: WOS:001093477800001

(<https://www.webofscience.com/wos/woscc/full-record/WOS:001093477800001>)

#腫瘍学

NOTCH1とCREBBPの同時変異は、EGFR変異NSCLCの完全切除における術後補助療法の有益性に悪影響を及ぼす：

第III相IMPACT試験のトランスレーショナル・リサーチについての論文

Ikeda S, Tsuboi M, Sakai K, Misumi T, Akamatsu H, Shoda H, Sakakura N, Nakamura A, Ohde Y, Hayashi H, Okishio K, Okada M, Yoshino I, Okami J, Takahashi K, Ikeda N, Tanahashi M, Tambo Y, Saito H, Toyooka S, Inokawa H, Chen-Yoshikawa T, Yokoyama T, **Okamoto T**, Yanagitani N, Oki M, Takahama M, Sawa K, Tada H, Nakagawa K, Mitsudomi T, Nishio K

NOTCH1 and CREBBP co-mutations negatively affect the benefit of adjuvant therapy in completely resected EGFR-mutated NSCLC: translational research of phase III IMPACT study

Mol Oncol. 2023 OCT 28;

Journal Impact Factor 2021: 7.449

PMID: 37864465 (<https://pubmed.ncbi.nlm.nih.gov/37864465>) DOI: 10.1002/1878-0261.13542

(<https://doi.org/10.1002/1878-0261.13542>) WoS: WOS:001091737600001

(<https://www.webofscience.com/wos/woscc/full-record/WOS:001091737600001>)

#ヘルスケア科学 #サービス

成人T細胞白血病・リンパ腫以外の疾患に対する造血幹細胞移植後のヒトT細胞白血病ウイルスI型キャリアの転帰：日本全国調査についての論文

Nakano N, Nakasone H, Fujii S, Shinohara A, Suzuki R, Utsunomiya A, Eto T, Morishima S, Ikegame K, Kakinoki Y, Matsuoka KI, Mori Y, **Suehiro Y**, Uchida N, Ito A, Doki N, Ozawa Y, Kanda J, Kanda Y, Fukuda T, Atsuta Y, Ogata M

Outcomes in human T-cell leukemia virus type I carriers after hematopoietic stem cell transplantation for diseases other than adult T cell leukemia/lymphoma: a Japanese national survey

Lancet Reg Health-W Pac. 2023 NOV;40

Journal Impact Factor 2021: 8.559

DOI: 10.1016/j.lanwpc.2023.100902 (<https://doi.org/10.1016/j.lanwpc.2023.100902>) WoS:

WOS:001088777500001 (<https://www.webofscience.com/wos/woscc/full-record/WOS:001088777500001>)

#心臓 #循環器系

肺葉下切除術後の末梢性ガラス混濁優位肺癌患者の長期予後についての論文

Yoshino I, Moriya Y, Suzuki K, Wakabayashi M, Saji H, Aokage K, Suzuki M, Ito H, Matsumoto I, Kobayashi M, **Okamoto T**, Okada M, Yamashita M, Ikeda N, Nakamura S, Kataoka T, Tsuboi M, Watanabe SC, WJOGAJCOG

Long-term outcome of patients with peripheral ground-glass opacity-dominant lung cancer after sublobar resections

J Thorac Cardiovasc Surg. 2023 OCT;166(4):1222-1231.

Journal Impact Factor 2021: 6.439

PMID: 37704343 (<https://pubmed.ncbi.nlm.nih.gov/37704343>) DOI: 10.1016/j.jtcvs.2023.01.019

(<https://doi.org/10.1016/j.jtcvs.2023.01.019>) WoS: WOS:001080034500001

(<https://www.webofscience.com/wos/woscc/full-record/WOS:001080034500001>)

#栄養 #栄養学 #ランダム化比較試験 #第II相試験

頭頸部癌におけるプラチナ製剤ベースの化学放射線療法により誘発される粘膜炎の予防に対するβ-ヒドロキシ-β-メチル酪酸、アルギニンおよびグルタミンの有効性：第II相試験についての論文

Kuroki K, Rikimaru F, Kunitake N, Toh S, Higaki Y, Masuda M

Efficacy of beta-hydroxy-beta-methylbutyrate, arginine, and glutamine for the prevention of mucositis induced by platinum-based chemoradiation in head and neck cancer: A phase II study
Clin Nutr ESPEN. 2023 OCT;57:730-734.

Journal Impact Factor 2021: N/A

PMID: 37739730 (<https://pubmed.ncbi.nlm.nih.gov/37739730>) DOI: 10.1016/j.clnesp.2023.08.027

(<https://doi.org/10.1016/j.clnesp.2023.08.027>) WoS: WOS:001072360100001

(<https://www.webofscience.com/wos/woscc/full-record/WOS:001072360100001>)

#腫瘍学

リンパ節転移のない唾液腺様嚢胞癌患者の予後スコアについての論文

Shimoda H, Teshima M, Murase T, Nagao T, Kusafuka K, Nakaguro M, Urano M, **Taguchi K**, Yamamoto H, Kano S, Tada Y, Tsukahara K, Okami K, Onitsuka T, Fujimoto Y, Kawakita D, Sakurai K, Hanai N, Nagao T, Kawata R, Hato N, Nibu K, Inagaki H

Prognostic scores for patients with salivary adenoid cystic carcinoma without lymph node metastasis

Oral Oncol. 2023 OCT;145

Journal Impact Factor 2021: 5.972

PMID: 37487445 (<https://pubmed.ncbi.nlm.nih.gov/37487445>) DOI: 10.1016/j.oraloncology.2023.106491

(<https://doi.org/10.1016/j.oraloncology.2023.106491>) WoS: WOS:001057740500001

(<https://www.webofscience.com/wos/woscc/full-record/WOS:001057740500001>)

#腫瘍学

マイクロサテライト不安定性高値大腸癌における免疫逃避機構のサブクローン性集積についての論文

Kobayashi Y, Niida A, Nagayama S, Saeki K, Haeno H, Takahashi KK, Hayashi S, Ozato Y, Saito H, Hasegawa T, Nakamura H, Tobo T, Kitagawa A, **Sato K**, Shimizu D, Hirata H, Hisamatsu Y, Tushima T, Yonemura Y, Masuda T, Mizuno S, Kawazu M, Kohsaka S, Ueno T, Mano H, Ishihara S, Uemura M, Mori M, Doki Y, Eguchi H, Oshima M, Suzuki Y, Shibata T, Mimori K

Subclonal accumulation of immune escape mechanisms in microsatellite instability-high colorectal cancers

Br J Cancer. 2023 OCT 19;129(7):1105-1118.

Journal Impact Factor 2021: 9.082

PMID: 37596408 (<https://pubmed.ncbi.nlm.nih.gov/37596408>) DOI: 10.1038/s41416-023-02395-8

(<https://doi.org/10.1038/s41416-023-02395-8>) WoS: WOS:001051826800004

(<https://www.webofscience.com/wos/woscc/full-record/WOS:001051826800004>)

#病理学

腺様嚢胞癌におけるMYB/MYBL1および周辺MYB/MYBL1関連遺伝子再配列の景観についての論文

Ueda K, Murase T, Kawakita D, Nagao T, Kusafuka K, Nakaguro M, Urano M, Yamamoto H, **Taguchi K**, Kano S, Tada Y, Tsukahara K, Okami K, Onitsuka T, Fujimoto Y, Sakurai K, Hanai N, Nagao T, Kawata R, Hato N, Nibu K, Inagaki H

The Landscape of MYB/MYBL1-and Peri-MYB/MYBL1-Associated Rearrangements in Adenoid Cystic Carcinoma

Mod Pathol. 2023 OCT;36(10)

Journal Impact Factor 2021: 8.209

PMID: 37423587 (<https://pubmed.ncbi.nlm.nih.gov/37423587>) DOI: 10.1016/j.modpat.2023.100274

(<https://doi.org/10.1016/j.modpat.2023.100274>) WoS: WOS:001049774600001

(<https://www.webofscience.com/wos/woscc/full-record/WOS:001049774600001>)

#腫瘍学

第3章 抗がん剤治療による腎障害の管理（抗がん剤治療中の腎障害管理に関する臨床診療ガイドラインより） 2022年についての論文

Ando Y, Nishiyama H, Shimodaira H, Takano N, Sakaida E, Matsumoto K, Nakanishi K, Sakai H, Tsukamoto S, Komine K, Yasuda Y, Kato T, Fujiwara Y, Koyama T, Kitamura H, Kuwabara T, Yonezawa A, **Okumura Y**, Yakushijin K, Nozawa K, Goto H, Matsubara T, Hoshino J, Yanagita M, Comm Clinical Practice Guidelines **Chapter 3: Management of kidney injury caused by cancer drug therapy, from clinical practice guidelines for the management of kidney injury during anticancer drug therapy 2022** **Int J Clin Oncol.** 2023 OCT;28(10):1315-1332.

Journal Impact Factor 2021: 3.85

PMID: 37453935 (<https://pubmed.ncbi.nlm.nih.gov/37453935>) DOI: 10.1007/s10147-023-02382-2 (<https://doi.org/10.1007/s10147-023-02382-2>) WoS: WOS:001029090200001 (<https://www.webofscience.com/wos/woscc/full-record/WOS:001029090200001>)

#腫瘍学

進行胃癌におけるTP53遺伝子の変異スペクトルとニボルマブ治療効果との相関 (TP53MUT試験) についての論文

Ando K, Nakamura Y, Kitao H, Shimokawa M, Kotani D, Bando H, Nishina T, Yamada T, Yuki S, Narita Y, Hara H, Ohta T, **Esaki T**, Hamamoto Y, Kato K, Yamamoto Y, Minashi K, Ohtsubo K, Izawa N, Kawakami H, Kato T, Satoh T, Okano N, Tsuji A, Yamazaki K, Yoshino T, Maehara Y, Oki E

Mutational spectrum of TP53 gene correlates with nivolumab treatment efficacy in advanced gastric cancer (TP53MUT study)

Br J Cancer. 2023 OCT 5;129(6):1032-1039.

Journal Impact Factor 2021: 9.082

PMID: 37532830 (<https://pubmed.ncbi.nlm.nih.gov/37532830>) DOI: 10.1038/s41416-023-02378-9 (<https://doi.org/10.1038/s41416-023-02378-9>) WoS: WOS:001042425000002 (<https://www.webofscience.com/wos/woscc/full-record/WOS:001042425000002>)

#心臓 #循環器系 #レビュー論文

2019年中の日本における胸部・心臓血管外科手術 日本胸部外科学会年報についての論文

Minatoya K, Comm Sci Affairs, Japanese Assoc Thoracic Surg, Sato Y, **Toh Y**, Abe T, Endo S, Hirata Y, Ishida M, Iwata H, Kamei T, Kawaharada N, Kawamoto S, Kohno K, Kumamaru H, Matsumiya G, Motomura N, Nakahara R, Okada M, Saji H, Saito A, Shimizu H, Suzuki K, Takemura H, Taketani T, Takeuchi H, Tatsuishi W, Yamamoto H, Yasuda T, Watanabe M, Yoshimura N, Tsuchida M, Sawa Y

Thoracic and cardiovascular surgeries in Japan during 2019 Annual report by the Japanese Association for Thoracic Surgery

Gen Thorac Cardiovasc Surg. 2023 OCT;71(10):595-628.

Journal Impact Factor 2021: 1.227

PMID: 37470949 (<https://pubmed.ncbi.nlm.nih.gov/37470949>) DOI: 10.1007/s11748-023-01945-4 (<https://doi.org/10.1007/s11748-023-01945-4>) WoS: WOS:001033696300001 (<https://www.webofscience.com/wos/woscc/full-record/WOS:001033696300001>)

#消化器病学 #肝臓学

膵管腺癌切除後の予後予測因子としての悪液質指数についての論文

Shimagaki T, Sugimachi K, Mano Y, Onishi E, Iguchi T, Nakashima Y, Sugiyama M, Yamamoto M, Morita M, Toh Y

Cachexia index as a prognostic predictor after resection of pancreatic ductal adenocarcinoma **Ann Gastroent Surg.** 2023 NOV;7(6):977-986.

Journal Impact Factor 2021: 3.583

PMID: 37927935 (<https://pubmed.ncbi.nlm.nih.gov/37927935>) DOI: 10.1002/ags3.12686 (<https://doi.org/10.1002/ags3.12686>) WoS: WOS:000976773200001 (<https://www.webofscience.com/wos/woscc/full-record/WOS:000976773200001>)